ApconiX at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

ApconiX takes part in 2 sessions at ACT 2026 in San Antonio, and exhibits at Booth 213. Its program covers why seizure risk differs between species and how expert-led data science supports safety assessment, from choosing a drug target to weighing the evidence.

OrganizationACT 2026 Attendance
ApconiX
Alderley Edge, UK
apconix.com
Consultancies
UK toxicology consultancy with its own lab: hERG and cardiac screening, in vitro seizure assays, target safety assessments and nonclinical regulatory support.
Booth
Exhibiting at Booth 213
Mon, Nov 169:30am–6:30pmTue, Nov 178:00am–4:30pm
Talk
Wed Nov 18
9:40am–10:15am
Part of Modernizing Drug Development: Advanced Translational Methodologies for CNS and PNS Risk Assessment (S13)
Mechanistic Insights into Species-Specific Seizure Susceptibility (S13-3)
Safety pharmacology · Neurotoxicology
Talk
Wed Nov 18
12:00pm–12:55pm

Explore the full ACT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in San Antonio. Leave your work email and we’ll be in touch.

Privacy

Download the full ACT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from ApconiX

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction